TY  - JOUR
AU  - Sousa-Pinto, B.
AU  - Louis, R.
AU  - Anto, J.M.
AU  - Amaral, R.
AU  - Sá-Sousa, A.
AU  - Czarlewski, W.
AU  - Brussino, L.
AU  - Canonica, G.W.
AU  - Chaves, Loureiro C.
AU  - Cruz, A.A.
AU  - Gemicioglu, B.
AU  - Haahtela, T.
AU  - Kupczyk, M.
AU  - Kvedariene, V.
AU  - Larenas-Linnemann, D.E.
AU  - Okamoto, Y.
AU  - Ollert, M.
AU  - Pfaar, O.
AU  - Pham-Thi, N.
AU  - Puggioni, F.
AU  - Regateiro, F.S.
AU  - Romantowski, J.
AU  - Sastre, J.
AU  - Scichilone, N.
AU  - Taborda-Barata, L.
AU  - Ventura, M.T.
AU  - Agache, I.
AU  - Bedbrook, A.
AU  - Becker, S.
AU  - Bergmann, K.C.
AU  - Bosnic-Anticevich, S.
AU  - Bonini, M.
AU  - Boulet, L.-P.
AU  - Brusselle, G.
AU  - Buhl, R.
AU  - Cecchi, L.
AU  - Charpin, D.
AU  - de, Blay F.
AU  - Del, Giacco S.
AU  - Ivancevich, J.C.
AU  - Jutel, M.
AU  - Klimek, L.
AU  - Kraxner, Helga
AU  - Kuna, P.
AU  - Laune, D.
AU  - Makela, M.
AU  - Morais-Almeida, M.
AU  - Nadif, R.
AU  - Niedoszytko, M.
AU  - Papadopoulos, N.G.
AU  - Papi, A.
AU  - Patella, V.
AU  - Pétré, B.
AU  - Rivero, Yeverino D.
AU  - Robalo, Cordeiro C.
AU  - Roche, N.
AU  - Rouadi, P.W.
AU  - Samolinski, B.
AU  - Savouré, M.
AU  - Shamji, M.H.
AU  - Sheikh, A.
AU  - Suppli, Ulrik C.
AU  - Usmani, O.S.
AU  - Valiulis, A.
AU  - Yorgancioglu, A.
AU  - Zuberbier, T.
AU  - Fonseca, J.A.
AU  - Costa, E.M.
AU  - Bousquet, J.
TI  - Adherence to inhaled corticosteroids and long-acting β2-agonists in asthma: A MASK-air study
JF  - PULMONOLOGY
J2  - PULMONOLOGY
VL  - 31
PY  - 2025
IS  - 1
PG  - 10
SN  - 2531-0429
DO  - 10.1016/j.pulmoe.2023.07.004
UR  - https://m2.mtmt.hu/api/publication/34103124
ID  - 34103124
AB  - Introduction: Adherence to controller medication is a major problem in asthma management, being difficult to assess and tackle. mHealth apps can be used to assess adherence. We aimed to assess the adherence to inhaled corticosteroids+long-acting β2-agonists (ICS+LABA) in users of the MASK-air® app, comparing the adherence to ICS+formoterol (ICS+F) with that to ICS+other LABA. Materials and methods: We analysed complete weeks of MASK-air® data (2015-2022; 27 countries) from patients with self-reported asthma and ICS+LABA use. We compared patients reporting ICS+F versus ICS+other LABA on adherence levels, symptoms and symptom-medication scores. We built regression models to assess whether adherence to ICS+LABA was associated with asthma control or short-acting beta-agonist (SABA) use. Sensitivity analyses were performed considering the weeks with no more than one missing day. Results: In 2598 ICS+LABA users, 621 (23.9%) reported 4824 complete weeks and 866 (33.3%) reported weeks with at most one missing day. Higher adherence (use of medication ≥80% of weekly days) was observed for ICS+other LABA (75.1%) when compared to ICS+F (59.3%), despite both groups displaying similar asthma control and work productivity. The ICS+other LABA group was associated with more days of SABA use than the ICS+F group (median=71.4% versus 57.1% days). Each additional weekly day of ICS+F use was associated with a 4.1% less risk in weekly SABA use (95%CI=-6.5;-1.6%;p=0.001). For ICS+other LABA, the percentage was 8.2 (95%CI=-11.6;-5.0%;p<0.001). Conclusions: In asthma patients adherent to the MASK-air app, adherence to ICS+LABA was high. ICS+F users reported lower adherence but also a lower SABA use and a similar level of control. © 2023 Sociedade Portuguesa de Pneumologia
LA  - English
DB  - MTMT
ER  - 

TY  - JOUR
AU  - Sousa-Pinto, B.
AU  - Costa, E.M.
AU  - Vieira, R.J.
AU  - Klimek, L.
AU  - Czarlewski, W.
AU  - Pfaar, O.
AU  - Bedbrook, A.
AU  - Amaral, R.
AU  - Brussino, L.
AU  - Kvedariene, V.
AU  - Larenas-Linnemann, D.E.
AU  - Iinuma, T.
AU  - Pham-Thi, N.
AU  - Regateiro, F.S.
AU  - Taborda-Barata, L.
AU  - Ventura, M.T.
AU  - Ansotegui, I.J.
AU  - Bergmann, K.C.
AU  - Canonica, G.W.
AU  - Cardona, V.
AU  - Cecchi, L.
AU  - Cherrez-Ojeda, I.
AU  - Cingi, C.
AU  - Cruz, A.A.
AU  - Del, Giacco S.
AU  - Devillier, P.
AU  - Fokkens, W.J.
AU  - Gemicioglu, B.
AU  - Haahtela, T.
AU  - Ivancevich, J.C.
AU  - Kuna, P.
AU  - Kraxner, Helga
AU  - Laune, D.
AU  - Louis, R.
AU  - Makris, M.
AU  - Morais-Almeida, M.
AU  - Mösges, R.
AU  - Niedoszytko, M.
AU  - Papadopoulos, N.G.
AU  - Patella, V.
AU  - Pereira, A.M.
AU  - Reitsma, S.
AU  - Robles-Velasco, K.
AU  - Rouadi, P.W.
AU  - Samolinski, B.
AU  - Sova, M.
AU  - Toppila-Salmi, S.K.
AU  - Sastre, J.
AU  - Valiulis, A.
AU  - Yorgancioglu, A.
AU  - Zidarn, M.
AU  - Zuberbier, T.
AU  - Fonseca, J.A.
AU  - Bousquet, J.
ED  - Anto, J.M. / Collaborator
ED  - Kupczyk, M. / Collaborator
ED  - Kulus, M. / Collaborator
ED  - Roche, N. / Collaborator
ED  - Scichilone, N. / Collaborator
ED  - Almeida, R. / Collaborator
ED  - Bosnic-Anticevich, S. / Collaborator
ED  - Braido, F. / Collaborator
ED  - Loureiro, C.C. / Collaborator
ED  - de, Vries G. / Collaborator
ED  - Giuliano, A.F.M. / Collaborator
ED  - Jácome, C. / Collaborator
ED  - Kaidashev, I. / Collaborator
ED  - Louis, G. / Collaborator
ED  - Lourenço, O. / Collaborator
ED  - Makela, M. / Collaborator
ED  - Maurer, M. / Collaborator
ED  - Mullol, J. / Collaborator
ED  - Nadif, R. / Collaborator
ED  - O’Hehir, R. / Collaborator
ED  - Okamoto, Y. / Collaborator
ED  - Ollert, M. / Collaborator
ED  - Olze, H. / Collaborator
ED  - Pétré, B. / Collaborator
ED  - Puggioni, F. / Collaborator
ED  - Romantowski, J. / Collaborator
ED  - Rivero-Yeverino, D. / Collaborator
ED  - Rodriguez-Gonzalez, M. / Collaborator
ED  - Sá-Sousa, A. / Collaborator
ED  - Savouré, M. / Collaborator
ED  - Serpa, F.S. / Collaborator
ED  - Shamji, M.H. / Collaborator
ED  - Sheikh, A. / Collaborator
ED  - Ulrik, C.S. / Collaborator
ED  - Sofiev, M. / Collaborator
ED  - Sperl, A. / Collaborator
ED  - Todo-Bom, A. / Collaborator
ED  - Tsiligianni, I. / Collaborator
ED  - Valovirta, E. / Collaborator
ED  - van, Eerd M. / Collaborator
ED  - Blain, H. / Collaborator
ED  - Boulet, L.-P. / Collaborator
ED  - Brusselle, G. / Collaborator
ED  - Buhl, R. / Collaborator
ED  - Charpin, D. / Collaborator
ED  - Casale, T. / Collaborator
ED  - Chivato, T. / Collaborator
ED  - Correia-de-Sousa, J. / Collaborator
ED  - Corrigan, C. / Collaborator
ED  - de, Blay F. / Collaborator
ED  - Dykewicz, M. / Collaborator
ED  - Fiocchi, A. / Collaborator
ED  - Giovannini, M. / Collaborator
ED  - Jassem, E. / Collaborator
ED  - Jutel, M. / Collaborator
ED  - Keil, T. / Collaborator
ED  - La, Grutta S. / Collaborator
ED  - Lipworth, B. / Collaborator
ED  - Papi, A. / Collaborator
ED  - Pépin, J.-L. / Collaborator
ED  - Quirce, S. / Collaborator
ED  - Cordeiro, C.R. / Collaborator
ED  - Torres, M.J. / Collaborator
ED  - Usmani, O.S. / Collaborator
ED  - Bonini, M. / Collaborator
ED  - Gradauskiene, B. / Collaborator
ED  - Brightling, C. / Collaborator
TI  - Adherence to Treatment in Allergic Rhinitis During the Pollen Season in Europe: A MASK-air Study
JF  - CLINICAL AND EXPERIMENTAL ALLERGY
J2  - CLIN EXP ALLERGY
VL  - 55
PY  - 2025
IS  - 3
SP  - 226
EP  - 238
PG  - 13
SN  - 0954-7894
DO  - 10.1111/cea.70004
UR  - https://m2.mtmt.hu/api/publication/36012692
ID  - 36012692
LA  - English
DB  - MTMT
ER  - 

TY  - CHAP
AU  - Hirschberg, Andor
AU  - Kraxner, Helga
ED  - Szekanecz, Zoltán
ED  - Nagy, György
ED  - Szűcs, Gabriella
TI  - Fül-orr-gégészeti allergiák
T2  - Klinikai immunológia
PB  - Medicina Könyvkiadó
CY  - Budapest
SN  - 9789632269467
PY  - 2025
SP  - 864
EP  - 872
PG  - 9
UR  - https://m2.mtmt.hu/api/publication/36052072
ID  - 36052072
LA  - Hungarian
DB  - MTMT
ER  - 

TY  - JOUR
AU  - Sousa-Pinto, B.
AU  - Savoure, M.
AU  - Vieira, R.J.
AU  - Amaral, R.
AU  - Czarlewski, W.
AU  - Bedbrook, A.
AU  - Valiulis, A.
AU  - Kvedariene, V.
AU  - Brussino, L.
AU  - Gemicioǧlu, B.
AU  - Haahtela, T.
AU  - Klimek, L.
AU  - Kraxner, Helga
AU  - Larenas-Linnemann, D.E.
AU  - Pfaar, O.
AU  - Regateiro, F.S.
AU  - Samoliński, B.
AU  - Taborda-Barata, L.
AU  - Toppila-Salmi, S.
AU  - Ventura, M.T.
AU  - Ansótegui, I.J.
AU  - Braido, F.
AU  - Canonica, G.W.
AU  - Cecchi, L.
AU  - Cruz, A.A.
AU  - Devillier, P.
AU  - Fokkens, W.J.
AU  - Gil-Mata, S.
AU  - Ivancevich, J.C.
AU  - Kuna, P.
AU  - Kupczyk, M.
AU  - Louis, G.
AU  - Louis, R.
AU  - Makris, M.
AU  - Monti, M.
AU  - Mullol, J.
AU  - Nadif, R.
AU  - Niedoszytko, M.
AU  - Okamoto, Y.
AU  - Ollert, M.
AU  - Papadopoulos, N.G.
AU  - Patella, V.
AU  - Pawankar, R.
AU  - Pereira, A.M.
AU  - Pétré, B.
AU  - Pham-Thi, N.
AU  - Roche, N.
AU  - Rouadi, P.W.
AU  - Sastre, J.
AU  - Scichilone, N.
AU  - Sheikh, A.
AU  - Sova, M.
AU  - Todo‑Bom, A.
AU  - Yorgancioǧlu, A.
AU  - Zidarn, M.
AU  - Antò, J.M.
AU  - Zuberbier, T.
AU  - Fonseca, J.A.
AU  - Bousquet, J.
TI  - Allergic Rhinitis and its Impact on Asthma (ARIA) Classes in MASK-air Users
JF  - JOURNAL OF INVESTIGATIONAL ALLERGOLOGY AND CLINICAL IMMUNOLOGY
J2  - J INVEST ALLERG CLIN IMMUNOL
VL  - 35
PY  - 2025
IS  - 5
SP  - 373
EP  - 383
PG  - 11
SN  - 1018-9068
DO  - 10.18176/jiaci.1047
UR  - https://m2.mtmt.hu/api/publication/36391236
ID  - 36391236
LA  - English
DB  - MTMT
ER  - 

TY  - JOUR
AU  - Xu, Xinni
AU  - Ludanyi, Kristof Peter
AU  - Juratli, Jerry Hadi
AU  - Nemeth, Fruzsina
AU  - Nagy, Dávid
AU  - Kraxner, Helga
AU  - Hummel, Thomas
TI  - Real-World Outcomes of 3-Month Olfactory Training on Post-COVID-19 Parosmia
JF  - ORL-JOURNAL FOR OTO-RHINO-LARYNGOLOGY AND ITS RELATED SPECIALTIES
J2  - ORL J OTO-RHINO-LARY
VL  - 87
PY  - 2025
IS  - 4
SP  - 153
EP  - 161
PG  - 9
SN  - 0301-1569
DO  - 10.1159/000549019
UR  - https://m2.mtmt.hu/api/publication/36847011
ID  - 36847011
AB  - Introduction: Post-COVID-19 parosmia can be protracted and psychologically distressing. The effect of olfactory training (OT) on parosmia is still unclear. The primary objective was to investigate the effect of 3 months of OT on COVID-19-related parosmia. The secondary objectives were to study whether improvement in olfactory quantitative function and compliance to OT influenced improvement in parosmia. Methods: This prospective cohort study was conducted from October 5, 2022, to February 7, 2023, at a tertiary smell and taste clinic. Patients with persistent post-COVID-19 parosmia were instructed to perform OT twice daily for 3 months. Improvement in parosmia was measured using self-rated intensity and pleasantness scales, a structured parosmia questionnaire, and the Sniffin' Sticks Parosmia Test (which measures hedonic direction and range). Quantitative olfactory function was measured with Sniffin' Sticks to determine the threshold, discrimination, and identification (TDI) score. Pre- and post-OT assessment of parosmia and quantitative olfactory function was performed. Compliance to OT was calculated as a percentage of the number of OT sessions performed over the expected number of training sessions over 3 months. Results: Thirty-eight patients (mean age 41.8 [+/- 13.3] years, 12 [31.6%] males) were recruited. After 3 months, 52.6% (n = 20) reported perceived improvement in parosmia. There was improvement in perceived pleasantness (-2.0 [-3.0 to -1.0] vs. -3.0 [-4.0 to -2.0], p = 0.027), hedonic range (2.4 [+/- 1.3] vs. 1.9 [+/- 1.6], p = 0.023), and TDI (27.9 [+/- 7.4] vs. 25.2 [+/- 7.2], p = 0.001) from baseline. All measures of parosmia did not differ significantly between patients who achieved the minimum clinically important difference of >= 5.5 in TDI scores versus those who did not. Patients who had >70% compliance to OT displayed more significant improvements in hedonic range (1.1 [+/- 1.1] vs. 0.2 [+/- 1.3] p = 0.04) compared to those who were less compliant. Conclusion: COVID-19-related parosmia and olfactory dysfunction improved with OT over 3 months. Improvement in olfactory function does not necessarily improve parosmia perception. However, compliance with OT appears to have an effect on improvement in parosmia.
LA  - English
DB  - MTMT
ER  - 

TY  - JOUR
AU  - Kiricsi, Ágnes
AU  - Bella, Zsolt
AU  - Kraxner, Helga
AU  - Szalóki, Tibor
AU  - Fent, Zoltán
AU  - Liktor, Balázs
AU  - Huszka, J
AU  - Laszlo, P
AU  - Gobol, D
AU  - Helfferich, F
AU  - Vaska, Z
AU  - Piski, Zalán
AU  - Juhasz-Loisch, L
AU  - Horváth, Barnabás
AU  - Galantai, D
AU  - Krisztin, N
AU  - Tóth, László
AU  - Bodi, A
AU  - Matuz, Mária
AU  - Lujber, László
AU  - Hirschberg, Andor
TI  - Real-life effectiveness of dupilumab in chronic rhinosinusitis with nasal polyps: results from eight Hungarian centres with 12-month follow-up
JF  - RHINOLOGY
J2  - RHINOLOGY
VL  - 62
PY  - 2024
IS  - 4
SP  - 410
EP  - 420
PG  - 11
SN  - 0300-0729
DO  - 10.4193/Rhin23.278
UR  - https://m2.mtmt.hu/api/publication/34915949
ID  - 34915949
N1  - * Megosztott szerzőség
AB  - Background: Research on the immune mechanism behind chronic rhinosinusitis (CRS) has revealed various new endotypes, leading to targeted therapies, especially for severe uncontrolled CRS. Biologics are novel therapeutic strategies providing targeted treatment for the difficult-to-treat recalcitrant CRSwNP patients. Dupilumab is a fully human-derived monoclonal antibody that binds to IL4Rα, inhibiting the signalling of both IL-4 and IL-13. In Hungary, it is approved for the treatment of uncontrolled CRSwNP according to criteria based on the EPOS2020 and the Hungarian guidelines. Methodology: This study aimed to collect and evaluate real-world therapeutic data of CRSwNP patients treated with dupilumab. One hundred thirty-five patients from eight different referral centres have been enrolled in this study, who received dupilumab since 2020. All subjects were adult patients (>18 years) with uncontrolled CRSwNP. Baseline data collection included demographics, medical history, previous surgeries, related comorbidities, total endoscopic nasal polyp score (NPS), SNOT22, nasal congestion parameters measured with visual analogue scale (VAS) and nasal obstruction evaluation scale (NOSE), loss of smell score (LSS) and eosinophil count. 300 mg dupilumab was administered subcutaneously every second week. Follow up visits were performed after 6 and 12 months. Results: After 6 and 12 months of treatment significant improvement was detected in all clinical parameters. Safety was proved, no severe side effects occurred, and no rescue treatment was necessary. Conclusions: Our real-life findings show that continuous dupilumab treatment is effective and safe in daily clinical practice in CRSwNP and other type 2 comorbidities such as bronchial asthma and NERD.
LA  - English
DB  - MTMT
ER  - 

TY  - JOUR
AU  - Bousquet, J.
AU  - Schünemann, H.J.
AU  - Sousa-Pinto, B.
AU  - Zuberbier, T.
AU  - Togias, A.
AU  - Samolinski, B.
AU  - Bedbrook, A.
AU  - Czarlewski, W.
AU  - Hofmann-Apitius, M.
AU  - Litynska, J.
AU  - Vieira, R.J.
AU  - Anto, J.M.
AU  - Fonseca, J.A.
AU  - Brozek, J.
AU  - Bognanni, A.
AU  - Brussino, L.
AU  - Canonica, G.W.
AU  - Cherrez-Ojeda, I.
AU  - Cruz, A.A.
AU  - Vecillas, L.D.L.
AU  - Dykewicz, M.
AU  - Gemicioglu, B.
AU  - Giovannini, M.
AU  - Haahtela, T.
AU  - Jacobs, M.
AU  - Jacomelli, C.
AU  - Klimek, L.
AU  - Kvedariene, V.
AU  - Larenas-Linnemann, D.E.
AU  - Louis, G.
AU  - Lourenço, O.
AU  - Leemann, L.
AU  - Morais-Almeida, M.
AU  - Neves, A.L.
AU  - Nadeau, K.C.
AU  - Nowak, A.
AU  - Palamarchuk, Y.
AU  - Palkonen, S.
AU  - Papadopoulos, N.G.
AU  - Parmelli, E.
AU  - Pereira, A.M.
AU  - Pfaar, O.
AU  - Regateiro, F.S.
AU  - Savouré, M.
AU  - Taborda-Barata, L.
AU  - Toppila-Salmi, S.K.
AU  - Torres, M.J.
AU  - Valiulis, A.
AU  - Ventura, M.T.
AU  - Williams, S.
AU  - Yepes-Nuñez, J.J.
AU  - Yorgancioglu, A.
AU  - Zhang, L.
AU  - Zuberbier, J.
AU  - Abdul, Latiff A.H.
AU  - Abdullah, B.
AU  - Agache, I.
AU  - Al-Ahmad, M.
AU  - Al-Nesf, M.A.
AU  - Al, Shaikh N.A.
AU  - Amaral, R.
AU  - Ansotegui, I.J.
AU  - Asllani, J.
AU  - Balotro-Torres, M.C.
AU  - Bergmann, K.-C.
AU  - Bernstein, J.A.
AU  - Bindslev-Jensen, C.
AU  - Blaiss, M.S.
AU  - Bonaglia, C.
AU  - Bonini, M.
AU  - Bossé, I.
AU  - Braido, F.
AU  - Caballero-Fonseca, F.
AU  - Camargos, P.
AU  - Carreiro-Martins, P.
AU  - Casale, T.
AU  - Castillo-Vizuete, J.-A.
AU  - Cecchi, L.
AU  - Teixeira, M.D.C.
AU  - Chang, Y.-S.
AU  - Loureiro, C.C.
AU  - Christoff, G.
AU  - Ciprandi, G.
AU  - Cirule, I.
AU  - Correia-de-Sousa, J.
AU  - Costa, E.M.
AU  - Cvetkovski, B.
AU  - de, Vries G.
AU  - Del, Giacco S.
AU  - Devillier, P.
AU  - Dokic, D.
AU  - Douagui, H.
AU  - Durham, S.R.
AU  - Enecilla, M.L.
AU  - Fiocchi, A.
AU  - Fokkens, W.J.
AU  - Fontaine, J.-F.
AU  - Gawlik, R.
AU  - Gereda, J.E.
AU  - Gil-Mata, S.
AU  - Giuliano, A.F.M.
AU  - Gotua, M.
AU  - Gradauskiene, B.
AU  - Guzman, M.A.
AU  - Hossny, E.
AU  - Hrubiško, M.
AU  - Iinuma, T.
AU  - Irani, C.
AU  - Ispayeva, Z.
AU  - Ivancevich, J.C.
AU  - Jartti, T.
AU  - Jeseňák, M.
AU  - Julge, K.
AU  - Jutel, M.
AU  - Kaidashev, I.
AU  - Bennoor, K.S.
AU  - Khaltaev, N.
AU  - Kirenga, B.
AU  - Kraxner, Helga
AU  - Kull, I.
AU  - Kulus, M.
AU  - Kuna, P.
AU  - Kupczyk, M.
AU  - Kurchenko, A.
AU  - La, Grutta S.
AU  - Lane, S.
AU  - Miculinic, N.
AU  - Lee, S.M.
AU  - Le, Thi Tuyet L.
AU  - Lkhagvaa, B.
AU  - Louis, R.
AU  - Mahboub, B.
AU  - Makela, M.
AU  - Makris, M.
AU  - Maurer, M.
AU  - Melén, E.
AU  - Milenkovic, B.
AU  - Mohammad, Y.
AU  - Moniuszko, M.
AU  - Montefort, S.
AU  - Moreira, A.
AU  - Moreno, P.
AU  - Mullol, J.
AU  - Nadif, R.
AU  - Nakonechna, A.
AU  - Navarro-Locsin, C.G.
AU  - Neffen, H.E.
AU  - Nekam, K.
AU  - Niedoszytko, M.
AU  - Nunes, E.
AU  - Nyembue, D.
AU  - O'Hehir, R.
AU  - Ollert, M.
AU  - Ohta, K.
AU  - Okamoto, Y.
AU  - Okubo, K.
AU  - Olze, H.
AU  - Padukudru, M.A.
AU  - Palomares, O.
AU  - Pali-Schöll, I.
AU  - Panzner, P.
AU  - Palosuo, K.
AU  - Park, H.S.
AU  - Passalacqua, G.
AU  - Patella, V.
AU  - Pawankar, R.
AU  - Pétré, B.
AU  - Pitsios, C.
AU  - Plavec, D.
AU  - Popov, T.A.
AU  - Puggioni, F.
AU  - Quirce, S.
AU  - Raciborski, F.
AU  - Ramonaité, A.
AU  - Recto, M.
AU  - Repka-Ramirez, S.
AU  - Roberts, G.
AU  - Robles-Velasco, K.
AU  - Roche, N.
AU  - Rodriguez-Gonzalez, M.
AU  - Romualdez, J.A.
AU  - Rottem, M.
AU  - Rouadi, P.W.
AU  - Salapatas, M.
AU  - Sastre, J.
AU  - Serpa, F.S.
AU  - Sayah, Z.
AU  - Scichilone, N.
AU  - Senna, G.
AU  - Sisul, J.C.
AU  - Solé, D.
AU  - Soto-Martinez, M.E.
AU  - Sova, M.
AU  - Sozinova, O.
AU  - Stevanovic, K.
AU  - Ulrik, C.S.
AU  - Szylling, A.
AU  - Tan, F.M.
AU  - Tantilipikorn, P.
AU  - Todo-Bom, A.
AU  - Tomic-Spiric, V.
AU  - Tsaryk, V.
AU  - Tsiligianni, I.
AU  - Urrutia-Pereira, M.
AU  - Rostan, M.V.
AU  - Sofiev, M.
AU  - Valovirta, E.
AU  - Van, Eerd M.
AU  - Van, Ganse E.
AU  - Vasankari, T.
AU  - Vichyanond, P.
AU  - Viegi, G.
AU  - Wallace, D.
AU  - Wang, D.Y.
AU  - Waserman, S.
AU  - Wong, G.
AU  - Worm, M.
AU  - Yusuf, O.M.
AU  - Zaitoun, F.
AU  - Zidarn, M.
TI  - Concepts for the Development of Person-Centered, Digitally Enabled, Artificial Intelligence–Assisted ARIA Care Pathways (ARIA 2024)
JF  - JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY: IN PRACTICE
J2  - J ALLERGY CLIN IMMUNOL PRACT
VL  - 12
PY  - 2024
IS  - 10
SP  - 2648
EP  - 2668.e2
PG  - 23
SN  - 2213-2198
DO  - 10.1016/j.jaip.2024.06.040
UR  - https://m2.mtmt.hu/api/publication/35420761
ID  - 35420761
LA  - English
DB  - MTMT
ER  - 

TY  - JOUR
AU  - Sousa-Pinto, B.
AU  - Schünemann, H.J.
AU  - Sá-Sousa, A.
AU  - Vieira, R.J.
AU  - Amaral, R.
AU  - Anto, J.M.
AU  - Klimek, L.
AU  - Czarlewski, W.
AU  - Mullol, J.
AU  - Pfaar, O.
AU  - Bedbrook, A.
AU  - Brussino, L.
AU  - Kvedariene, V.
AU  - Larenas-Linnemann, D.E.
AU  - Okamoto, Y.
AU  - Ventura, M.T.
AU  - Agache, I.
AU  - Ansotegui, I.J.
AU  - Bergmann, K.C.
AU  - Bosnic-Anticevich, S.
AU  - Canonica, G.W.
AU  - Cardona, V.
AU  - Carreiro-Martins, P.
AU  - Casale, T.
AU  - Cecchi, L.
AU  - Chivato, T.
AU  - Chu, D.K.
AU  - Cingi, C.
AU  - Costa, E.M.
AU  - Cruz, A.A.
AU  - Del, Giacco S.
AU  - Devillier, P.
AU  - Eklund, P.
AU  - Fokkens, W.J.
AU  - Gemicioglu, B.
AU  - Haahtela, T.
AU  - Ivancevich, J.C.
AU  - Ispayeva, Z.
AU  - Jutel, M.
AU  - Kuna, P.
AU  - Kaidashev, I.
AU  - Khaitov, M.
AU  - Kraxner, Helga
AU  - Laune, D.
AU  - Lipworth, B.
AU  - Louis, R.
AU  - Makris, M.
AU  - Monti, R.
AU  - Morais-Almeida, M.
AU  - Mösges, R.
AU  - Niedoszytko, M.
AU  - Papadopoulos, N.G.
AU  - Patella, V.
AU  - Pham-Thi, N.
AU  - Regateiro, F.S.
AU  - Reitsma, S.
AU  - Rouadi, P.W.
AU  - Samolinski, B.
AU  - Sheikh, A.
AU  - Sova, M.
AU  - Todo-Bom, A.
AU  - Taborda-Barata, L.
AU  - Toppila-Salmi, S.
AU  - Sastre, J.
AU  - Tsiligianni, I.
AU  - Valiulis, A.
AU  - Vandenplas, O.
AU  - Wallace, D.
AU  - Waserman, S.
AU  - Yorgancioglu, A.
AU  - Zidarn, M.
AU  - Zuberbier, T.
AU  - Fonseca, J.A.
AU  - Bousquet, J.
TI  - Consistent trajectories of rhinitis control and treatment in 16,177 weeks: The MASK-air® longitudinal study
JF  - ALLERGY: EUROPEAN JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
J2  - ALLERGY
VL  - 78
PY  - 2023
IS  - 4
SP  - 968
EP  - 983
PG  - 16
SN  - 0105-4538
DO  - 10.1111/all.15574
UR  - https://m2.mtmt.hu/api/publication/33424326
ID  - 33424326
LA  - English
DB  - MTMT
ER  - 

TY  - JOUR
AU  - Molnár, András
AU  - Maihoub, Stefani
AU  - Mavrogeni, Panayiota
AU  - Krasznai, Magdolna
AU  - Tamás, László
AU  - Kraxner, Helga
TI  - The Correlation between the Results of the Sniffin’ Sticks Test, Demographic Data, and Questionnaire of Olfactory Disorders in a Hungarian Population after a SARS-CoV-2 Infection
JF  - JOURNAL OF CLINICAL MEDICINE
J2  - J CLIN MED
VL  - 12
PY  - 2023
IS  - 3
PG  - 12
SN  - 2077-0383
DO  - 10.3390/jcm12031041
UR  - https://m2.mtmt.hu/api/publication/33605666
ID  - 33605666
N1  - András Molnár and Stefani Maihoub authors contributed equally to this work.
AB  - Background: After a severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection, smell disorders frequently occur, significantly affecting patients’ quality of life (QoL). Methods: 110 patients with persistent olfactory disorder after coronavirus infection were enrolled. These patients underwent chemosensory testing using the Sniffin’ Sticks test, and completed the Questionnaire of Olfactory Disorders (QOD). Results: 30% of the patients reported anosmia, and 70% reported hyposmia. Upon comparing subjective and chemosensory testing categories, good category matching was observed in 75.3% (i.e., anosmia based on both methods in 10 and hyposmia in 48 cases). Statistical analysis using the Chi-square test revealed a significant result (p = 0.001 *). Between the TDI (i.e., Threshold, Discrimination, Identification) results of the three subjective report groups (i.e., hyposmia, anosmia, and parosmia), no significant differences were observed. When the TDI and QOD results were compared, no consistent significant correlations were found in most TDI and QOD outcomes. Between the TDI and Scale 2 results, a significant, although slight correlation was observed by the Spearman’s (rho = 0.213, p = 0.027 *) and Pearson’s (rho = 0.201, p = 0.037 *) tests. Conclusions: The nonsignificant correlation between objective and subjective methods suggests that these results should be interpreted independently. Moreover, adequate management is essential even in mild cases.
LA  - English
DB  - MTMT
ER  - 

TY  - JOUR
AU  - Bousquet, J.
AU  - Anto, J.M.
AU  - Sousa-Pinto, B.
AU  - Czarlewski, W.
AU  - Bedbrook, A.
AU  - Haahtela, T.
AU  - Klimek, L.
AU  - Pfaar, O.
AU  - Kuna, P.
AU  - Kupczyk, M.
AU  - Regateiro, F.S.
AU  - Samolinski, B.
AU  - Valiulis, A.
AU  - Yorgancioglu, A.
AU  - Arnavielhe, S.
AU  - Basagaña, X.
AU  - Bergmann, K.C.
AU  - Bosnic-Anticevich, S.
AU  - Brussino, L.
AU  - Canonica, G.W.
AU  - Cardona, V.
AU  - Cecchi, L.
AU  - Chaves-Loureiro, C.
AU  - Costa, E.
AU  - Cruz, A.A.
AU  - Gemicioglu, B.
AU  - Fokkens, W.J.
AU  - Ivancevich, J.C.
AU  - Kraxner, Helga
AU  - Kvedariene, V.
AU  - Larenas-Linnemann, D.E.
AU  - Laune, D.
AU  - Louis, R.
AU  - Makris, M.
AU  - Maurer, M.
AU  - Melén, E.
AU  - Micheli, Y.
AU  - Morais-Almeida, M.
AU  - Mullol, J.
AU  - Niedoszytko, M.
AU  - Okamoto, Y.
AU  - Papadopoulos, N.G.
AU  - Patella, V.
AU  - Pham-Thi, N.
AU  - Rouadi, P.W.
AU  - Sastre, J.
AU  - Scichilone, N.
AU  - Sheikh, A.
AU  - Sofiev, M.
AU  - Taborda-Barata, L.
AU  - Toppila-Salmi, S.
AU  - Tsiligianni, I.
AU  - Valovirta, E.
AU  - Ventura, M.T.
AU  - Vieira, R.J.
AU  - Zidarn, M.
AU  - Amaral, R.
AU  - Ansotegui, I.J.
AU  - Bédard, A.
AU  - Benveniste, S.
AU  - Bewick, M.
AU  - Bindslev-Jensen, C.
AU  - Blain, H.
AU  - Bonini, M.
AU  - Bourret, R.
AU  - Braido, F.
AU  - Carreiro-Martins, P.
AU  - Charpin, D.
AU  - Cherrez-Ojeda, I.
AU  - Chivato, T.
AU  - Chu, D.K.
AU  - Cingi, C.
AU  - Del, Giacco S.
AU  - de, Blay F.
AU  - Devillier, P.
AU  - De, Vries G.
AU  - Doulaptsi, M.
AU  - Doyen, V.
AU  - Dray, G.
AU  - Fontaine, J.-F.
AU  - Gomez, R.M.
AU  - Hagemann, J.
AU  - Heffler, E.
AU  - Hofmann, M.
AU  - Jassem, E.
AU  - Jutel, M.
AU  - Keil, T.
AU  - Kritikos, V.
AU  - Kull, I.
AU  - Kulus, M.
AU  - Lourenço, O.
AU  - Mathieu-Dupas, E.
AU  - Menditto, E.
AU  - Mösges, R.
AU  - Murray, R.
AU  - Nadif, R.
AU  - Neffen, H.
AU  - Nicola, S.
AU  - O’Hehir, R.
AU  - Olze, H.
AU  - Palamarchuk, Y.
AU  - Pépin, J.-L.
AU  - Pétré, B.
AU  - Picard, R.
AU  - Pitsios, C.
AU  - Puggioni, F.
AU  - Quirce, S.
AU  - Raciborski, F.
AU  - Reitsma, S.
AU  - Roche, N.
AU  - Rodriguez-Gonzalez, M.
AU  - Romantowski, J.
AU  - Sá-Sousa, A.
AU  - Serpa, F.S.
AU  - Savouré, M.
AU  - Shamji, M.H.
AU  - Sova, M.
AU  - Sperl, A.
AU  - Stellato, C.
AU  - Todo-Bom, A.
AU  - Tomazic, P.V.
AU  - Vandenplas, O.
AU  - Van, Eerd M.
AU  - Vasankari, T.
AU  - Viart, F.
AU  - Waserman, S.
AU  - Fonseca, J.A.
AU  - Zuberbier, T.
TI  - Digitally-enabled, patient-centred care in rhinitis and asthma multimorbidity: The ARIA-MASK-air® approach
JF  - CLINICAL AND TRANSLATIONAL ALLERGY
J2  - CLIN TRANSL ALLERGY
VL  - 13
PY  - 2023
IS  - 1
PG  - 30
SN  - 2045-7022
DO  - 10.1002/clt2.12215
UR  - https://m2.mtmt.hu/api/publication/33626642
ID  - 33626642
LA  - English
DB  - MTMT
ER  -